EuroAPI Header EuroAPI Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Pharma Submits Letter Of Intent For A Clinical Trial Application For A Phase II Study In Patients With COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Data From Phase II study ATTRACT in Patients with COVID-19 Published Online: Vicore Pharma Holding","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore's Digital Therapeutic For IPF Patients Shows Nearly 50% Anxiety Reduction In Pilot Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Initiates Clinical Proof-Of-Concept Study of Endothelial Dysfunction","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Reports Positive Results from Phase 2a AIR Trial of Buloxibutid in IPF","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for Buloxibutid

    Menu

    Buloxibutid

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Vicore Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vicore Reports Positive Results from Phase 2a AIR Trial of Buloxibutid in IPF

              Details:

              C21 (buloxibutid) is an angiotensin II type 2 receptor agonist, which is currently being evaluated for the treatment of patients with idiopathic pulmonary fibrosis.

              Lead Product(s): Buloxibutid

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: C21

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 20, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Vicore Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vicore Initiates Clinical Proof-Of-Concept Study of Endothelial Dysfunction

              Details:

              C21 is an angiotensin II type 2 receptor agonist, which s being developed for the treatment endothelial dysfunction (reflecting blood vessel health) in patients with type-2-diabetes-mellitus.

              Lead Product(s): Buloxibutid

              Therapeutic Area: Endocrinology Product Name: C21

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 03, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Vicore Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vicore's Digital Therapeutic For IPF Patients Shows Nearly 50% Anxiety Reduction In Pilot Study

              Details:

              C21 is a small molecule compound, which is in clinical development for the treatment of IPF and COVID-19. The experimental programme will assess the potential of C21 for addressing fibrosis, inflammation and vasculopathy in a variety of diseases such as IPF.

              Lead Product(s): Buloxibutid

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: C21

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 06, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Vicore Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Positive Data From Phase II study ATTRACT in Patients with COVID-19 Published Online: Vicore Pharma Holding

              Details:

              The results show restoration of lung function in COVID-19 on top of corticosteroids and remdesivir with the company's oral drug C21, suggesting that C21 can become an important complement to vaccines to combat the COVID-19 pandemic.

              Lead Product(s): Buloxibutid

              Therapeutic Area: Infections and Infectious Diseases Product Name: VP01

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 01, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Vicore Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vicore Pharma Submits Letter Of Intent For A Clinical Trial Application For A Phase II Study In Patients With COVID-19

              Details:

              Vicore Pharma has submitted a Letter of Intent to file a clinical trial application to the UK regulatory agency for a phase II study with its proprietary compound C21 in patients with COVID-19.

              Lead Product(s): Buloxibutid

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 31, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              With Fermion, start the journey of your innovative API.
              Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
              Post Enquiry
              POST ENQUIRY